DeCure for Hepatitis, Alcoholic

Alcoholic hepatitis is a common condition with a high mortality; in the most severe forms, inpatient mortality can reach 50–75%. The abstracts reviewed here offer no evidence for any drug that improves survival in this disease. One 2009 paper discusses pentoxifylline only as a theoretical reappraisal linked to intestinal barrier breakdown, not as a proven therapy. The remaining literature is descriptive or mechanistic: a 2012 microarray study of peripheral blood identified 1,123 differentially expressed genes and 13 miRNAs in patients versus controls, with node genes including MAPK10, RAP1A, ADCY8, CBL and SOCS1, and key miRNAs such as hsa-miR-570 and hsa-miR-29. These findings are proposed as insights into pathogenesis, not as therapeutic targets with clinical validation.

The 2000 and 2011 papers emphasise general management rather than drug efficacy. Alcohol abstinence is described as the cornerstone of treatment, achievable with social support, Alcoholics Anonymous and sometimes pharmacological therapy, though no specific drug is named in the abstracts. Alcohol withdrawal should be anticipated and treated; complications of cirrhosis are managed as in any other patient. Patients are particularly prone to infections and malnutrition, which should be treated with broad-spectrum antibiotics and nutritional support respectively. A 2012 paper on endothelial markers and fibrosis notes that causal mechanisms are not fully understood, and histological features include hepatocellular injury, inflammation, Kupffer cell activation and hepatocellular regeneration.

No abstract reports a randomised trial, a response rate, or a survival benefit for any pharmacological agent. The 2013 Spanish-language papers are purely descriptive of the lesion spectrum (fatty liver, cirrhosis, foamy degeneration, cholestasis, chronic hepatitis, fibrosis, perivenular sclerosis) and add no interventional data. The evidence base is therefore limited to supportive care and abstinence, with molecular profiling still at the stage of hypothesis generation.

What is missing is decisive: no adequately powered randomised controlled trial of any candidate drug in alcoholic hepatitis, no validated biomarker to stratify patients by severity or likelihood of response, and no funding commitment to move the gene and miRNA signatures from microarray discovery into prospective clinical testing. Without those, the high inpatient mortality figures will not change.